A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05548296 · Acrivon Therapeutics
Enrollment · participant countRecorded edit
− Previous value
count: 401; type: ESTIMATED
+ Updated value
count: 350; type: ESTIMATED
ACRV
Acrivon Therapeutics
Company identity has not yet been verified
See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.
1Trials in this database
4Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2 Study of ACR-368 in Endometrial AdenocarcinomaNCT05548296 | Acrivon Therapeutics | Phase 2 | Recruiting | 2027-05-30Estimated |
Latest recorded trial changes
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05548296 · Acrivon Therapeutics
Primary completion dateRecorded edit
− Previous value
2026-10-31
+ Updated value
2027-05-30
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05548296 · Acrivon Therapeutics
Enrollment · participant countRecorded edit
− Previous value
count: 353; type: ESTIMATED
+ Updated value
count: 401; type: ESTIMATED
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05548296 · Acrivon Therapeutics
Primary outcomes · main study measuresText edit · unverified significance
− Previous value
measure: Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive.; measure: Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative.; measure: Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (All-Comers).
+ Updated value
measure: Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive.; measure: Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative.; measure: Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers).; measure: Arm 4: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers).
Check registry source · The saved outcome text may be shortened. Check the source for full wording.